Chugai Pharmaceutical
Mr. Toshiaki Itagaki (Head of Fin. Supervisory Division, CFO, Exec. VP & Director)
Dr. Osamu Okuda (Pres, CEO & Representative Director)
Toshiya Sasai (Exec. of Investor Relations Group & Corp. Communications Department)
Summary
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
History
Timeline
This is a timeline of important events of Chugai Pharmaceutical.
1925: Juzo Ueno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines
1927: Start of the first own production
1930: Salobrocanon, an analgesic and antipyretic is launched
1937: Calcium bromide production begins
1943: Name changed to Chugai Pharmaceutical Co., Ltd. based in Tokyo
1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga
1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt
1946: Construction of the plant in Kamagiishi
1951: Guronsan®, a drug to detoxify and restore liver function is launched
1952: Varsan®, a perspiration insecticide is launched
1955: Chugai became a public company
1956: The stock is listed on the Tokyo Stock Exchange
1957: Construction of the Ukima plant
1960: Establishment of a research center
1967: Foundation of Fukushima Kasai Co Ltd.
1961 – Developed patents for synthesis of vitamin A
1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd., after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
1971: Construction of the factory in Fujieda
1975: Picibanil®, a cancer drug is launched
1982: Opening of a branch in New York
1986: Opening of a branch in London
1989: Acquisition of Gen-Probe Incorporated
1990: Epogin® launched
1995 – Released acute promyelocytic sphere of leukemia drug treatment Vesanoid®
1996 – Released anti-viral chemotherapeutic agent Hivid®
1997 – Released HIV protease inhibitor Invirase®
1999 – Released immunosuppressive agent Cellcept®
2000 – Released antiemetic drug Kytril®, developed to combating the side effects of chemotherapy
2001 – Produced anti-influenza virus Tamiflu
2002: Start of the alliance with Roche
2003: Xeloda®, a cancer drug is launched
2005: Actemra® launched
2007: Copegus®, an antiviral, Avastin®, a cancer drug, and Tarceva®, a cancer drug launched
2011 – Produced Actemra®, a human IL-6 receptor monoclonal antibody for rheumatoid arthritis
2014: Launch of Kadcyla®, a cancer drug, Chugai Pharma China Co Ltd. founded
2015 – In March the company announced it would co-commercialise Athersys's stem cell therapy for ischemic strokes in Japan. The deal could yield upwards of US$205 million.
2016: Cooperation between Osaka University and Chugai
2018: Tecentriq®, a cancer drug is launched
2020 – FDA approved satralizumab for treatment of the orphan disease neuromyelitis optica
Mission
Our mission is to create innovative and life-changing products that will contribute to the health and well-being of people worldwide.
Vision
Our vision is to become the leading global pharmaceutical company through research and development of biotechnology and pharmaceutical products.
Key Team
Masahiko Uchida (Gen. Mang. of Corp. Communications Department)
Mr. Shinji Hidaka (Exec. VP and Head of Marketing & Sales Division)
Mr. Tsunanori Sato (VP and GM of Marketing & Sales Division)
Mr. Yoshiyuki Yano (Exec. VP & Head of HR Management Department)
Mr. Junichi Ebihara (Exec. VP)
Dr. Yoshiaki Ohashi (SVP & Full-time Audit Supervisory Board Member)
Mr. Tetsuya Yamaguchi (Exec. VP and Head of Project & Lifecycle Management Unit)
Recognition and Awards
References
Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.
Mr. Toshiaki Itagaki (Head of Fin. Supervisory Division, CFO, Exec. VP & Director)
Dr. Osamu Okuda (Pres, CEO & Representative Director)
Toshiya Sasai (Exec. of Investor Relations Group & Corp. Communications Department)